PATENT CLAIM ANALYSIS

Application Number: 16308457
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-09
Patent Classification: ["514", "234200"]

Abstract:
A crystalline modification of triazolopyrazine derivatives binds to a hepatocyte growth factor (HGF) to activate phosphorylation, thereby significantly inhibiting the activity of c-Met kinase triggering cell proliferation, migration, and formation of new blood vessels. Therefore, the compound of the present application may be effectively used for the treatment or prevention of various hyper proliferative disorders mediated by hyper proliferation activation of cells and excessive angiogenesis.

Claim (Index 11):
The crystalline modification type IV compound of  claim 10 , wherein the angles of 2\u03b8 representing XRD peaks further include 14.84\u00b0, 16.33\u00b0, 16.89\u00b0, 17.79\u00b0, and 19.92\u00b0 (\u00b02\u03b8, \u00b10.1\u00b0 using Cu-K\u03b11 radiation).

Metadata:
- Claim Count in Document: 80.0
- Percentile: 98.0
- Lexical Diversity: 1.2807
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13141142', '13143831', '14609137', '14158182', '13728350']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7599230281596504
- 35 USC 102 Novelty (BERT): 0.5314360830412501
- Combined Prediction Score: 0.7370743336478104
- Mean Citation Score: 301.166224
- Max Citation Score: 334.4524
- Similarity Product: 256.8561761064053

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test